Aphria (APHA) Cut to “Sell” at Zacks Investment Research

Aphria (NYSE:APHA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “Aphria Inc. produces, supplies and sells medical cannabis primarily in Canada. The company offers sativa, indica and hybrid medical marijuana products, as well as cannabis oils. Aphria Inc. is headquartered in Leamington, Canada. “

Several other research analysts also recently commented on APHA. ValuEngine downgraded Aphria from a “buy” rating to a “hold” rating in a research note on Monday. Clarus Securities began coverage on Aphria in a research note on Tuesday. They issued a “buy” rating and a $22.75 price objective on the stock. Seaport Global Securities began coverage on Aphria in a research report on Thursday, February 21st. They set a “buy” rating and a $18.00 target price for the company. CIBC began coverage on Aphria in a research report on Friday, January 18th. They set a “neutral” rating for the company. Finally, Cormark set a $15.00 target price on Aphria and gave the stock a “buy” rating in a research report on Saturday, February 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $15.69.

Shares of NYSE APHA traded down $0.17 during trading on Friday, hitting $7.65. The company had a trading volume of 10,303,985 shares, compared to its average volume of 6,846,421. Aphria has a 12 month low of $3.75 and a 12 month high of $16.86. The company has a market capitalization of $1.92 billion, a P/E ratio of 54.64 and a beta of 4.08.

Several large investors have recently added to or reduced their stakes in the stock. Winslow Evans & Crocker Inc. purchased a new position in Aphria during the 4th quarter valued at approximately $28,000. Intercontinental Wealth Advisors LLC purchased a new position in Aphria during the 4th quarter valued at approximately $28,000. Liberty Wealth Management LLC purchased a new position in Aphria during the 4th quarter valued at approximately $35,000. 1832 Asset Management L.P. purchased a new position in Aphria during the 4th quarter valued at approximately $50,000. Finally, Truvestments Capital LLC purchased a new position in Aphria during the 1st quarter valued at approximately $61,000. Hedge funds and other institutional investors own 10.39% of the company’s stock.

Aphria Company Profile

Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.

Recommended Story: Why is insider trading harmful?

Get a free copy of the Zacks research report on Aphria (APHA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aphria (NYSE:APHA)

Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.